VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
WST
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
WSTWest Pharmaceutical Services, Inc.
$375.97$26.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksWSTP/E History

WST logoWest Pharmaceutical Services, Inc. (WST) P/E Ratio History

Expensive

Trading at 55.3x vs 5Y avg 43.2x · 95th percentile · Material premium to history · Data 1990–2026

Current P/E (TTM)
55.3x
+28% vs 5Y avg
5Y Avg P/E
43.2x
Median 45.6x
5Y Percentile
95th
Upper end of range
PEG Ratio
6.68
Premium to growth
5-Year P/E Range
55.3x
Min29.6xMedian45.6xMax55.8x
TTM EPS$7.92
Price$375.97
Earnings Yield1.81%
EPS Growth (1Y)1.6%
EPS Growth (5Y)8.3%

Loading P/E history...

P/E Ratio Analysis

As of September 24, 2026, West Pharmaceutical Services, Inc. (WST) trades at a price-to-earnings ratio of 55.3x, with a stock price of $375.97 and trailing twelve-month earnings per share of $7.92.

The current P/E is 28% above its 5-year average of 43.2x. Over the past five years, WST's P/E has ranged from a low of 29.6x to a high of 55.8x, placing the current valuation at the 95th percentile of its historical range.

Compared to the Healthcare sector median P/E of 23.7x, WST trades at a 133% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.

The PEG ratio of 6.68 (P/E divided by 2% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, WST commands a significant premium over the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our WST DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

WST Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
55.3vs23.7
+133%
Above Sector
vs. S&P 500
55.3vs25.3
+118%
Above Market
PEG Analysis
6.68
P/E ÷ EPS Growth
PEG > 2 = Expensive
Based on 2% EPS growth (1Y)

WST P/E vs Peers

Drug delivery and infusion consumables peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ATR logoATRAptarGroup, Inc.
$8B21.21.65+6%
GTLS logoGTLSChart Industries, Inc.
$10B636.1--92%
AMCR logoAMCRAmcor plc
$20B18.0-+49%
SEE logoSEESealed Air Corporation
$6B12.3Lowest9.66+90%
PFE logoPFEPfizer Inc.
$161B20.7--4%
JNJ logoJNJJohnson & Johnson
$648B24.41.64+91%Best
MRK logoMRKMerck & Co., Inc.
$366B20.30.96Best+8%
ABBV logoABBVAbbVie Inc.
$469B111.9--1%
BDX logoBDXBecton, Dickinson and Company
$50B31.31.89-1%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

WST Historical P/E Data (1990–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q2-$359.00$7.8245.9x+26%
FY2026 Q1-$250.64$7.4933.5x-9%
FY2025 Q4Dec 31 2025$275.14$6.8040.5x+11%
FY2025 Q3-$262.33$6.7638.8x+6%
FY2025 Q2Jun 30 2025$218.80$6.6832.8x-10%
FY2025 Q1Mar 31 2025$223.88$6.3735.1x-4%
FY2024 Q4-$327.56$6.6949.0x+34%
FY2024 Q3Sep 30 2024$300.16$6.7444.5x+22%
FY2024 Q2Jun 30 2024$329.39$7.0346.9x+28%
FY2024 Q1Mar 31 2024$395.71$7.5852.2x+43%
FY2023 Q4Dec 31 2023$352.12$7.8844.7x+22%
FY2023 Q3Sep 30 2023$375.21$7.4150.6x+38%
FY2023 Q2Jun 30 2023$382.47$6.8655.8x+52%
FY2023 Q1Mar 31 2023$346.47$7.2947.5x+30%
FY2022 Q4Dec 31 2022$235.35$7.7330.4x-17%
FY2022 Q3Sep 30 2022$246.08$8.3029.6x-19%
FY2022 Q2-$302.37$9.0233.5x-8%
FY2022 Q1-$410.71$9.0045.6x+25%
FY2021 Q4Dec 31 2021$469.01$8.7053.9x+47%
FY2021 Q3-$424.54$8.0652.7x+44%
FY2021 Q2Jun 30 2021$359.10$6.8452.5x+44%
FY2021 Q1Mar 31 2021$281.78$5.5850.5x+38%
FY2020 Q4-$283.31$4.5861.9x+69%
FY2020 Q3Sep 30 2020$274.90$4.1366.6x+82%
FY2020 Q2-$227.17$3.7959.9x+64%
FY2020 Q1-$152.25$3.4644.0x+20%
FY2019 Q4-$150.33$3.2047.0x+28%
FY2019 Q3Sep 30 2019$141.82$3.0546.5x+27%
FY2019 Q2Jun 30 2019$125.15$3.0341.3x+13%
FY2019 Q1Mar 31 2019$110.20$2.9038.0x+4%
FY2018 Q4Dec 31 2018$98.03$2.7535.6x-3%
FY2018 Q3Sep 30 2018$123.47$2.0360.9x+67%
FY2018 Q2Jun 30 2018$99.29$1.9750.5x+38%
FY2018 Q1Mar 31 2018$88.29$1.7351.1x+40%
FY2017 Q4Dec 31 2017$98.67$1.9650.4x+38%
FY2017 Q3Sep 30 2017$96.26$2.5138.4x+5%
FY2017 Q2Jun 30 2017$94.52$2.3440.4x+10%
FY2017 Q1Mar 31 2017$81.61$2.4333.6x-8%
FY2016 Q4Dec 31 2016$84.83$1.9244.2x+21%
FY2016 Q3Sep 30 2016$74.50$1.8540.3x+10%
FY2016 Q2-$75.88$1.3755.4x+51%
FY2016 Q1-$69.32$1.1560.3x+65%
FY2015 Q4-$60.22$1.3046.3x+27%
FY2015 Q3Sep 30 2015$54.12$1.2842.3x+16%
FY2015 Q2-$58.08$1.6934.4x-6%
FY2015 Q1-$60.21$1.8332.9x-10%
FY2014 Q4Dec 31 2014$53.24$1.7630.3x-17%
FY2014 Q3-$44.76$1.6627.0x-26%
FY2014 Q2Jun 30 2014$42.18$1.6026.4x-28%
FY2014 Q1Mar 31 2014$44.05$1.5129.2x-20%
FY2013 Q4-$49.06$1.5831.1x-15%
FY2013 Q3Sep 30 2013$41.15$1.5526.5x-27%
FY2013 Q2Jun 30 2013$35.13$1.4025.1x-31%
FY2013 Q1Mar 31 2013$32.47$1.2027.1x-26%
FY2012 Q4Dec 31 2012$27.38$1.1623.6x-35%
FY2012 Q3Sep 30 2012$26.54$1.1123.9x-35%
FY2012 Q2Jun 30 2012$25.25$1.1422.1x-39%
FY2012 Q1Mar 31 2012$21.27$1.1917.9x-51%
FY2011 Q4Dec 31 2011$18.98$1.0617.9x-51%
FY2011 Q3Sep 30 2011$18.55$0.8920.8x-43%
FY2011 Q2-$21.88$0.9024.3x-34%
FY2011 Q1-$22.39$0.9324.0x-34%
FY2010 Q4Dec 31 2010$20.60$0.9322.1x-40%
FY2010 Q3-$17.16$1.1315.2x-58%
FY2010 Q2Jun 30 2010$18.25$1.1216.3x-55%
FY2010 Q1Mar 31 2010$20.98$1.0919.2x-47%
FY2009 Q4-$19.60$1.0418.8x-48%
FY2009 Q3Sep 30 2009$20.31$1.0120.1x-45%
FY2009 Q2-$17.43$0.9618.2x-50%
FY2009 Q1-$16.41$1.0915.1x-59%
FY2008 Q4Dec 31 2008$18.89$1.2415.2x-58%
FY2008 Q3-$24.41$1.0722.7x-38%
FY2008 Q2-$25.60$1.0524.3x-34%
FY2008 Q1Mar 31 2008$22.12$1.0121.8x-40%
FY2007 Q4Dec 31 2007$20.30$1.0219.8x-46%
FY2007 Q3Sep 30 2007$20.83$1.1618.0x-51%
FY2007 Q2Jun 30 2007$23.57$1.1820.0x-45%
FY2007 Q1Mar 31 2007$23.21$1.1220.7x-43%
FY2006 Q4Dec 31 2006$25.62$1.0125.4x-31%
FY2006 Q3Sep 30 2006$19.64$0.9720.2x-45%
FY2006 Q2Jun 30 2006$18.14$0.8920.4x-44%
FY2006 Q1Mar 31 2006$17.36$0.7822.3x-39%
FY2005 Q4Dec 31 2005$12.52$0.7117.6x-52%
FY2005 Q3Sep 30 2005$14.84$0.5427.7x-24%
FY2005 Q2-$14.03$0.4928.9x-21%
FY2005 Q1-$11.95$0.4228.7x-22%
FY2004 Q4Dec 31 2004$12.52$0.3338.4x+5%
FY2004 Q3-$10.43$0.6017.4x-52%
FY2004 Q2Jun 30 2004$10.58$0.6017.6x-52%
FY2004 Q1Mar 31 2004$9.35$0.5915.8x-57%
FY2003 Q4Dec 31 2003$8.47$0.5415.8x-57%
FY2003 Q3-$7.83$0.3124.9x-32%
FY2003 Q2Jun 30 2003$6.13$0.3120.0x-45%
FY2003 Q1Mar 31 2003$4.90$0.2817.6x-52%
FY2002 Q4-$6.10$0.3218.8x-49%
FY2001 Q3Sep 30 2001$6.15$0.02307.5x+741%
FY2001 Q1Mar 31 2001$5.84$0.03179.7x+391%
FY2000 Q4Dec 31 2000$6.14$0.03245.6x+571%
FY2000 Q3Sep 30 2000$5.81$0.4313.4x-63%
FY2000 Q2Jun 30 2000$5.41$0.4910.9x-70%
FY2000 Q1Mar 31 2000$6.33$0.5811.0x-70%
FY1999 Q4Dec 31 1999$7.73$0.6511.9x-67%
FY1999 Q3-$9.48$0.6414.8x-60%
FY1999 Q2Jun 30 1999$9.81$0.5916.5x-55%
FY1999 Q1Mar 31 1999$7.97$0.5614.1x-61%
FY1998 Q4-$8.92$0.1085.0x+132%
FY1998 Q3Sep 30 1998$7.19$0.07110.6x+202%
FY1998 Q2-$7.08$0.2330.8x-16%
FY1998 Q1-$7.53$0.2431.4x-14%
FY1997 Q4Dec 31 1997$7.44$0.6711.1x-70%
FY1997 Q3-$8.25$0.6912.0x-67%
FY1997 Q2Jun 30 1997$7.16$0.5313.5x-63%
FY1997 Q1Mar 31 1997$6.78$0.5013.6x-63%
FY1996 Q4-$7.06$0.2528.2x-23%
FY1996 Q3Sep 30 1996$6.47$0.2229.4x-20%
FY1996 Q2Jun 30 1996$7.50$0.1841.7x+14%
FY1996 Q1Mar 31 1996$5.81$0.1930.6x-16%
FY1995 Q4Dec 31 1995$5.88$0.4413.4x-63%
FY1995 Q3Sep 30 1995$7.03$0.4316.3x-55%
FY1995 Q2Jun 30 1995$7.00$0.4615.3x-58%
FY1995 Q1Mar 31 1995$6.38$0.4514.3x-61%
FY1994 Q4Dec 31 1994$6.88$0.4316.1x-56%
FY1994 Q3Sep 30 1994$6.38$0.4115.5x-58%
FY1994 Q2-$5.41$0.4013.6x-63%
FY1994 Q1-$6.19$0.3816.5x-55%
FY1993 Q4Dec 31 1993$6.13$0.3816.3x-55%
FY1993 Q3-$6.09$0.3517.3x-53%
FY1993 Q2Jun 30 1993$5.81$0.3417.0x-54%
FY1993 Q1Mar 31 1993$5.88$0.3417.6x-52%
FY1992 Q4-$5.63$0.3217.9x-51%
FY1991 Q3Sep 30 1991$4.16$0.0762.6x+71%
FY1991 Q2Jun 30 1991$4.00$0.0670.8x+94%
FY1991 Q1Mar 31 1991$3.56$0.0480.9x+121%
FY1990 Q4Dec 31 1990$3.06$0.0746.0x+26%

Average P/E for displayed period: 36.6x

Export Data
Consensus & Technical Research Suite
Open WST Terminal

WST Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

36+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

WST — Frequently Asked Questions

Quick answers to the most common questions about buying WST stock.

What is WST's P/E ratio?

West Pharmaceutical Services, Inc. (WST) trailing twelve-month P/E ratio is 55.3x, based on TTM diluted EPS of $7.92. The 5-year average P/E is 43.2x and the historical range spans 29.6x to 55.8x.

Is WST stock overvalued or undervalued?

WST trades at 55.3x P/E, above its 5-year average of 43.2x. The 95th percentile ranking within the 29.6x–55.8x historical range indicates a premium to historical valuation.

Is WST stock expensive?

Yes, WST is expensive relative to its own history. The current P/E of 55.3x is above the 5-year average of 43.2x and also above the Healthcare sector median of 23.7x. The stock sits at the 95th percentile of its 5-year valuation range.

What is WST's historical P/E range?

Over the past 5 years, WST's P/E ratio has ranged from 29.6x to 55.8x, with a median of 45.6x and an average of 43.2x. The current P/E of 55.3x places the stock at the 95th percentile of this range. Full historical data spans 1990–2026.

How does WST's P/E compare to the S&P 500?

WST trades at 55.3x P/E versus the S&P 500 median of 25.3x. The 119% premium to the market typically reflects higher expected earnings growth or quality.

How does WST's valuation compare to Healthcare peers?

West Pharmaceutical Services, Inc. P/E of 55.3x compares to the Healthcare sector median of 23.7x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is WST's PEG ratio?

WST PEG ratio is 6.68, based on a P/E of 55.3x and EPS growth of 1.6%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.

What is WST's earnings yield?

WST earnings yield is 1.81%, the inverse of its 55.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

WST P/E Ratio History (1990–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current45.9x
Period Avg43.2x
Range29.6x - 55.8x
Change-13%
20 quartersSep 30, 2021 - Jun 30, 2026